Clinical trial
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients…
NCT00116688 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00116688 |
|---|---|
| Title | Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
| Official title | An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombocytopenia, Idiopathic Thrombocytopenic Purpura |
| Intervention type | Biological |
| Interventions | Romiplostim |
| Enrollment | 313 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Jul 1, 2005 |
| Last update posted | Dec 18, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: